At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
voclosporindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg Twice Daily (BID) in Combination With Standard of Care in Patients With Active Lupus Nephritis
In Brief
A Phase 2 clinical trial evaluating voclosporin for Lupus Nephritis. Completed, enrolled 10 participants across 2 sites.
Detailed Summary
An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily (BID) in combination with standard of care in patients with active lupus nephritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Nephritis
CountriesMalaysia
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedOct 2016
Primary CompletionDec 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedOct 31, 2016
Enrollment StartJun 1, 2015
Primary CompletionDec 1, 2016
Study CompletionFeb 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.7 years ago
Interventions
voclosporindrug